A recent study found that the triple agonist retatrutide for GLP-1R, GIPR and GCGR substantially induced weight loss in obese adults, demonstrating the clinical potential of this triple agonist for obesity treatment.341 Another triple agonist for these receptors, LY3437943, was found to induce robust reductions in plasma glucose and bodyweight in overweight individuals with T2D demonstrating this triple agonist could be a future therapeutic option for T2D treatment.342. Here, GCGR is linked to obesity disorder.